CVRx, Inc. (CVRX) Financial Analysis & Valuation | Quarter Chart
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with r... more
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and com... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $80.67M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Kevin Hykes |
| IPO Date | 2021-06-30 | CAGR | 44.37% |
| Employees | 223 | Website | www.cvrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
CVRX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $147.97M | P/E | -1.5 | Forward P/E | -1.62 | PEG | — |
| P/S | 408.95 | P/B | 1262.96 | P/CF | -472.06 | P/FCF | -470.27 |
| Sales | $61.19M | Sales 1Y | 11.96% | Sales 3Y | 98.4% | Sales 5Y | 574.77% |
| EPS | $-2.02 | EPS 1Y | -5.71% | EPS 3Y | -5.71% | EPS 5Y | -97.05% |
| Sales QoQ | 6.34% | EPS QoQ | 6% | Sales QoQ Avg | 3.92% | EPS QoQ Avg | -1.37% |
| Gross Margin | 86.6% | Operating Margin | -79.49% | Profit Margin | -84.93% | ROCE | -59.93% |
| ROA | -56% | ROE | -152% | Altman Z Score | -7.88 | Piotroski Score | 2 |
| Current Ratio | 8.04 | Quick Ratio | 6.87 | Cash Ratio | 5.81 | Op. CF Ratio | -1.89 |
| Debt/Equity | 2.96 | Debt/Assets | 0.64 | Lt Debt/Equity | 2.96 | Lt Debt/Cap. | 0.75 |
| Intrst Cov. | -8.07 | Inventory Turnover | 0.63 | Asset Turnover | 0.66 | Receivables Turnover | 6.51 |
| Enterprise Value | $147.97M | P/E Ratio | -1.5 |
| Forward P/E | -1.62 | PEG Ratio | — |
| P/S Ratio | 408.95 | P/B Ratio | 1262.96 |
| P/CF Ratio | -472.06 | P/FCF Ratio | -470.27 |
| EPS | $-2.02 | EPS Growth 1Y | -5.71% |
| EPS Growth 3Y | -5.71% | EPS Growth 5Y | -97.05% |
| Revenue Growth 1Y | 11.96% | Gross Margin | 86.6% |
| Operating Margin | -79.49% | Profit Margin | -84.93% |
| ROE | -152% | ROA | -56% |
| ROCE | -59.93% | Current Ratio | 8.04 |
| Quick Ratio | 6.87 | Cash Ratio | 5.81 |
| Debt/Equity | 2.96 | Interest Coverage | -8.07 |
| Altman Z Score | -7.88 | Piotroski Score | 2 |
CVRx, Inc. (CVRX) valuation & financials
CVRx, Inc. (CVRX) has a market capitalization of $80.67M and trades at a price-to-earnings ratio of -1.5. It operates in the Healthcare sector (Medical - Devices).
CVRx, Inc.'s revenue grew +12.0% over the last year.
CVRx, Inc.'s next earnings report is scheduled for November 4, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.49. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)